| Literature DB >> 32966806 |
Lydia Boike1, Alexander G Cioffi1, Felix C Majewski1, Jennifer Co1, Nathaniel J Henning1, Michael D Jones2, Gang Liu2, Jeffrey M McKenna2, John A Tallarico2, Markus Schirle2, Daniel K Nomura3.
Abstract
MYC is a major oncogenic transcriptional driver of most human cancers that has remained intractable to direct targeting because much of MYC is intrinsically disordered. Here, we have performed a cysteine-reactive covalent ligand screen to identify compounds that could disrupt the binding of MYC to its DNA consensus sequence in vitro and also impair MYC transcriptional activity in situ in cells. We have identified a covalent ligand, EN4, that targets cysteine 171 of MYC within a predicted intrinsically disordered region of the protein. We show that EN4 directly targets MYC in cells, reduces MYC and MAX thermal stability, inhibits MYC transcriptional activity, downregulates multiple MYC transcriptional targets, and impairs tumorigenesis. We also show initial structure-activity relationships of EN4 and identify compounds that show improved potency. Overall, we identify a unique ligandable site within an intrinsically disordered region of MYC that leads to inhibition of MYC transcriptional activity.Entities:
Keywords: MYC; activity-based protein profiling; chemoproteomics; covalent ligand; cysteine; intrinsically disordered; transcription factor; undruggable
Mesh:
Substances:
Year: 2020 PMID: 32966806 PMCID: PMC7854864 DOI: 10.1016/j.chembiol.2020.09.001
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116